DCP3 Series Acknowledgments

*Disease Control Priorities*, third edition (DCP3) compiles the global health knowledge of institutions and experts from around the world, a task that required the efforts of over 500 individuals, including volume editors, chapter authors, peer reviewers, advisory committee members, and research and staff assistants. For each of these contributions we convey our acknowledgement and appreciation. First and foremost, we would like to thank our 31 volume editors who provided the intellectual vision for their volumes based on years of professional work in their respective fields, and then dedicated long hours to reviewing each chapter, providing leadership and guidance to authors, and framing and writing the summary chapters. We also thank our chapter authors who collectively volunteered their time and expertise to writing over 160 comprehensive, evidence-based chapters.

We owe immense gratitude to the institutional sponsor of this effort: The Bill & Melinda Gates Foundation. The Foundation provided sole financial support of the Disease Control Priorities Network. Many thanks to Program Officers Kathy Cahill, Philip Setel, Carol Medlin, and (currently) Damian Walker for their thoughtful interactions, guidance, and encouragement over the life of the project. We also wish to thank Jaime Sepúlveda for his longstanding support, including chairing the Advisory Committee for the second edition and, more recently, demonstrating his vision for DCP3 while he was a special advisor to the Gates Foundation. We are also grateful to the University of Washington’s Department of Global Health and successive chairs King Holmes and Judy Wasserheit for providing a home base for the DCP3 Secretariat, which included intellectual collaboration, logistical coordination, and administrative support.

We thank the many contractors and consultants who provided support to specific volumes in the form of economic analytical work, volume coordination, chapter drafting, and meeting organization: the Center for Disease Dynamics, Economics, & Policy; Center for Chronic Disease Control; Center for Global Health Research; Emory University; Evidence to Policy Initiative; Public Health Foundation of India; QURE Healthcare; University of California, San Francisco; University of Waterloo; University of Queensland; and the World Health Organization.

We are tremendously grateful for the wisdom and guidance provided by our advisory committee to the editors. Steered by Chair Anne Mills, the advisory committee assures quality and intellectual rigor of the highest order for DCP3.

The U.S. Institute of Medicine, in collaboration with the Interacademy Medical Panel, coordinated the peer-review process for all DCP3 chapters. Patrick Kelley, Gillian Buckley, Megan Ginivan, and Rachel Pittluck managed this effort and provided critical and substantive input.

The World Bank External and Corporate Relations Publishing and Knowledge division provided exceptional guidance and support throughout the demanding production and design process. We would particularly like to thank Carlos Rossel, the publisher; Mary Fisk, Nancy Lammers, Devlan O’Connor, Rumit Pancholi, and Deborah Naylor for their diligence and expertise. Additionally, we thank Jose de Buerba, Mario Trubiano, Yulia Ivanova, and Chiamaaka Osuagwu of the World Bank for providing professional counsel on communications and marketing strategies.

Several U.S. and international institutions contributed to the organization and execution of meetings that supported the preparation and dissemination of DCP3.
We would like to express our appreciation to the following institutions:

- University of Bergen, consultation on equity (June 2011)
- University of California, San Francisco, surgery volume consultations (April 2012, October 2013, February 2014)
- Institute of Medicine, first meeting of the Advisory Committee to the Editors ACE (March 2013)
- Harvard Global Health Institute, consultation on policy measures to reduce incidence of non-communicable diseases (July 2013)
- Institute of Medicine, systems strengthening meeting (September 2013)
- Center for Disease Dynamics, Economics, and Policy (Quality and Uptake meeting September 2013, reproductive and maternal health volume consultation November 2013)
- National Cancer Institute cancer consultation (November 2013)
- Union for International Cancer Control cancer consultation (November 2013, December 2014)

Carol Levin provided outstanding governance for cost and cost-effectiveness analysis. Stéphane Verguet added invaluable guidance in applying and improving the extended cost-effectiveness analysis method. Shane Murphy, Zachary Olson, Elizabeth Brouwer, and Kristen Danforth provided exceptional research assistance and analytic assistance. Brianne Adderley ably managed the budget and project processes. The efforts of these individuals were absolutely critical to producing this series and we are thankful for their commitment.
Hellen Gelband is Associate Director for Policy at the Center for Disease Dynamics, Economics & Policy (CDDEP). Her work spans infectious disease, particularly malaria and antibiotic resistance, and noncommunicable disease policy, mainly in low- and middle-income countries. Before joining CDDEP, then Resources for the Future, she conducted policy studies at the (former) Congressional Office of Technology Assessment, the Institute of Medicine of the U.S. National Academies, and a number of international organizations.

Prabhat Jha is the founding director of the Centre for Global Health Research at St. Michael’s Hospital and holds Endowed and Canada Research Chairs in Global Health in the Dalla Lana School of Public Health at the University of Toronto. He is lead investigator of the Million Death Study in India, which quantifies the causes of death and key risk factors in over two million homes over a 14-year period. He is also Scientific Director of the Statistical Alliance for Vital Events, which aims to expand reliable measurement of causes of death worldwide. His research includes the epidemiology and economics of tobacco control worldwide.

Rengaswamy Sankaranarayanan is head of the Early Detection and Prevention Section and the Screening Group at the World Health Organization’s International Agency for Research on Cancer (IARC) in Lyon, France. He was trained in radiation oncology at the University of Pittsburgh and the University of Cambridge. He is an expert in evaluating early detection strategies and has conducted trials of screening interventions for cervical, oral, and breast cancers in a number of low- and middle-income countries. Aided by collaborative relationships with other international and national organizations and individual researchers, he provides technical assistance to countries developing public health policies that include cancer. His manuals on early detection of cervical cancer have been translated into several languages, including Chinese, French, Hindi, Portuguese, Spanish and Turkish, and others.

Susan Horton is Professor at the University of Waterloo and holds the Centre for International Governance Innovation (CIGI) Chair in Global Health Economics in the Balsillie School of International Affairs there. She has consulted for the World Bank, the Asian Development Bank, several United Nations agencies, and the International Development Research Centre, among others in work carried out in over 20 low- and middle-income countries. She led the work on nutrition for the Copenhagen Consensus in 2008, when micronutrients were ranked as the top development priority. She has served as associate provost of graduate studies at the University of Waterloo, vice-president academic at Wilfrid Laurier University in Waterloo, and interim dean at the University of Toronto at Scarborough.

Dean T. Jamison

Dean Jamison is a Senior Fellow in Global Health Sciences at the University of California, San Francisco, and an Emeritus Professor of Global Health at the University of Washington. He previously held academic appointments at Harvard University and the
University of California, Los Angeles; he was an econo-
mist on the staff of the World Bank, where he was lead
author of the World Bank’s World Development Report
1993: Investing in Health. He was lead editor of DCP2.
He holds a PhD in economics from Harvard University
and is an elected member of the Institute of Medicine
of the U.S. National Academy of Sciences. He recently
served as Co-Chair and Study Director of The Lancet’s
Commission on Investing in Health.

Rachel Nugent
Rachel Nugent is a Research Associate Professor in
the Department of Global Health at the University
of Washington. She was formerly Deputy Director of
Global Health at the Center for Global Development,
Director of Health and Economics at the Population
Reference Bureau, Program Director of Health and
Economics Programs at the Fogarty International Center
of the National Institutes of Health, and senior econ-
omist at the Food and Agriculture Organization of
the United Nations. From 1991–97, she was associate
professor and department chair in economics at Pacific
Lutheran University. She has advised the World Health
Organization, the U.S. government, and nonprofit organ-
izations on the economics and policy environment of
noncommunicable diseases.

Hellen Gelband
See the list of Volume Editors.

Susan Horton
See the list of Volume Editors.

Prabhat Jha
See the list of Volume Editors.

Ramanan Laxminarayan
Ramanan Laxminarayan is Vice President for Research
and Policy at the Public Health Foundation of India, and
he directs the Center for Disease Dynamics, Economics
& Policy in Washington, D.C., and New Delhi. His
research deals with the integration of epidemiological
models of infectious diseases and drug resistance into
the economic analysis of public health problems. He was
one of the key architects of the Affordable Medicines
Facility for malaria, a novel financing mechanism to
improve access and delay resistance to antimalarial
drugs. In 2012, he created the Immunization Technical
Support Unit in India, which has been credited with
improving immunization coverage in the country. He
teaches at Princeton University.
Contributors

Isaac F. Adewole
University of Ibadan, Ibadan, Nigeria

Hemantha Amarasinghe
Institute of Oral Health, Maharagama, Sri Lanka

Benjamin O. Anderson
Fred Hutchinson Cancer Research Center, University of Washington, Seattle, Washington, United States

Federico G. Antillon
Universidad Francisco Marroquin, Guatemala City, Guatemala

Samira Asma
Centers for Disease Control and Prevention, Atlanta, Georgia, United States

 Rifat Atun
Harvard University, Cambridge, Massachusetts, United States

Rajendra A. Badwe
Tata Memorial Centre, Mumbai, India

Freddie Bray
International Agency for Research on Cancer, Lyon, France

Frank J. Chaloupka
University of Illinois at Chicago, Chicago, Illinois, United States

Ann Chao
National Cancer Institute, Bethesda, Maryland, United States

Chien-Jen Chen
National Taiwan University, Taipei, Taiwan, China

Wendong Chen
University of Toronto, Toronto, Canada

James Cleary
University of Wisconsin, Madison, Wisconsin, United States

Anil D'Cruz
Tata Memorial Hospital, Mumbai, India

Anna J. Dare
Centre for Global Health Research, St. Michael's Hospital, University of Toronto, Toronto, Canada

Lynette Denny
University of Cape Town, Groote Schuur Hospital, Cape Town, South Africa

Craig Earle
Cancer Care Ontario, Ontario Institute for Cancer Research, University of Toronto, Toronto, Canada

Silvia Franceschi
International Agency for Research on Cancer, Lyon, France

Cindy L. Gauvreau
Centre for Global Health Research, St. Michael’s Hospital, University of Toronto, Toronto, Canada

Hellen Gelband
Center for Disease Dynamics, Economics & Policy, Washington, DC, United States

Ophira M. Ginsburg
Dalla Lana School of Public Health, University of Toronto, Toronto, Canada; BRAC University, Dhaka, Bangladesh
Mary K. Gospodarowicz  
Princess Margaret Cancer Centre, Toronto, Canada

Thomas Gross  
National Cancer Institute, Bethesda, Maryland, United States

Prakash C. Gupta  
Healis Sehksaria Institute for Public Health, Mumbai, India

Sumit Gupta  
Toronto Hospital for Sick Children, Toronto, Canada

Sir Andrew Hall  
International Agency for Research on Cancer, Lyon, France

Mhamed Harif  
CHU Mohammed VI, Marrakesh, Morocco

Rolando Herrero  
International Agency for Research on Cancer, Lyon, France

Susan Horton  
University of Waterloo, Waterloo, Ontario, Canada

Scott C. Howard  
University of Tennessee Health Sciences Center, Memphis, Tennessee, United States

Stephen P. Hunger  
Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States

Andre Ilbawi  
MD Anderson Cancer Center, Houston, Texas, United States

Trijn Israels  
Academisch Medisch Centrum, Amsterdam, the Netherlands

David A. Jaffray  
Princess Margaret Cancer Centre, TECHNA Institute, Toronto, Ontario

Dean T. Jamison  
University of California, San Francisco, and University of Washington, Seattle, Washington, United States

Prabhat Jha  
Centre for Global Health Research, St. Michael's Hospital, Dalla Lana School of Public Health, University of Toronto, Toronto, Canada

Newell Johnson  
Griffith University, Gold Coast, Australia

Jamal Khader  
King Hussein Cancer Center, Amman, Jordan

Jane J. Kim  
Harvard University, Cambridge, Massachusetts, United States

Felicia Knaul  
Miami Institute for the Americas, and Miller School of Medicine, University of Miami, Florida, United States

Carol Levin  
University of Washington, Seattle, Washington, United States

Joseph Lipscomb  
Emory University, Atlanta, Georgia, United States

W. Thomas London  
Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States

Mary MacLennan  
Centre for Global Health Research, St. Michael's Hospital, University of Toronto, Toronto, Canada

Katherine A. McGlynn  
National Cancer Institute, Bethesda, Maryland, United States

Monika L. Metzger  
St. Jude Children’s Research Hospital, Memphis, Tennessee, United States

Raul H. Murillo  
National Cancer Institute of Colombia, Bogotá, Colombia

Zachary Olson  
University of Washington, Seattle, Washington, United States

Sherif Omar  
Cairo University, Cairo, Arab Republic of Egypt

Krishna Palipudi  
Centers for Disease Control and Prevention, Atlanta, Georgia, United States

C. S. Pramesh  
Tata Memorial Centre, Mumbai, India

You-Lin Qiao  
Cancer Hospital, Chinese Academy of Medical Sciences, Peking Union Medical College, Beijing, China

Linda Rabeneck  
Cancer Care Ontario, University of Toronto, Toronto, Canada

Preetha Rajaraman  
National Cancer Institute, Bethesda, Maryland, United States
Kunnambath Ramadas
Regional Cancer Centre, Trivandrum, India

Chinthanie Ramasundarahettige
Centre for Global Health Research, St. Michael’s Hospital, University of Toronto, Toronto, Canada

Timothy Rebbeck
University of Pennsylvania, Philadelphia, Pennsylvania, United States

Carlos Rodriguez-Galindo
Harvard University, Cambridge, Massachusetts, United States

Rengaswamy Sankaranarayanan
International Agency for Research on Cancer, Lyon, France

Monisha Sharma
University of Washington, Seattle, Washington, United States

Ju-Fang Shi
Cancer Institute, Chinese Academy of Medical Sciences, Peking Union Medical College, Beijing, China

Isabelle Soerjomataram
International Agency for Research on Cancer, Lyon, France

Lisa Stevens
National Cancer Institute, Bethesda, Maryland, United States

Sujha Subramanian
RTI International, Waltham, Massachusetts, United States

Richard Sullivan
Kings College London, King’s Health Partners, London, United Kingdom

Terrence Sullivan
University of Toronto, Canadian Partnership Against Cancer, Toronto, Canada

David B. Thomas
Fred Hutchinson Cancer Research Center, University of Washington, Seattle, Washington, United States

Edward L. Trimble
National Cancer Institute, Bethesda, Maryland, United States

Joann Trypuc
Princess Margaret Cancer Centre, Toronto, Canada

Stéphane Verguet
Department of Global Health and Population, Harvard T. H. Chan School of Public Health, Boston, Massachusetts, United States

Judith Wagner
Independent economic consultant, Bethesda, Maryland, United States

Shao-Ming Wang
Cancer Institute, Chinese Academy of Medical Sciences, Peking Union Medical College, Beijing, China

Christopher P. Wild
International Agency for Research on Cancer, Lyon, France

Pooja Yerramilli
Harvard Global Equity Initiative, Harvard University, Cambridge, Massachusetts, United States

Cheng-Har Yip
University of Malaya Medical Centre, Kuala Lumpur, Malaysia

Ayda Yurekli
Independent economist, Ithaca, New York, United States

Witold Zatonński
Maria Sklodowska-Curie Cancer Centre, Warsaw, Poland

Ann G. Zauber
Memorial Sloan-Kettering Cancer Center, New York, New York, United States

Fang-Hui Zhao
Cancer Institute/Hospital, Chinese Academy of Medical Sciences, Beijing, China
Advisory Committee to the Editors

Anne Mills, Chair
Professor, London School of Hygiene & Tropical Medicine, London, United Kingdom

Olusoji Adeyi
Director, Health, Nutrition and Population Global Practice, World Bank, Washington, DC, United States

Kesetebirhan Admasu
Minister of Health, Addis Ababa, Ethiopia

George Alleyne
Director Emeritus, Pan American Health Organization, Washington, DC, United States

Ala Alwan
Director, World Health Organization, Regional Office for the Eastern Mediterranean, Cairo, Arab Republic of Egypt

Rifat Atun
Professor, Global Health Systems, Harvard University, Boston, Massachusetts, United States

Zulfiqar Bhutta
Chair, Division of Women and Child Health, Aga Khan University Hospital, Karachi, Pakistan

Agnes Binagwaho
Minister of Health, Kigali, Rwanda

Mark Blecher
Senior Health Advisor, South Africa Treasury Department, Cape Town, South Africa

Patricia Garcia
Dean, School of Public Health, Universidad Peruana Cayetano Heredia, Lima, Peru

Roger Glass
Director, Fogarty International Center, National Institutes of Health, Bethesda, Maryland, United States

Amanda Glassman
Director, Global Health Policy, Center for Global Development, Washington, DC, United States

Glenda Gray
Executive Director, Perinatal HIV Research Unit, Chris Hani Baragwanath Hospital, Johannesburg, South Africa

Demissie Habte
Chair of Board of Trustees, International Clinical Epidemiological Network, Addis Ababa, Ethiopia

Richard Horton
Editor, The Lancet, London, United Kingdom

Edward Kirumira
Dean, Faculty of Social Sciences, Makerere University, Kampala, Uganda

Peter Lachmann
Professor, University of Cambridge, Cambridge, United Kingdom

Lai Meng Looi
Professor, University of Malaya, Kuala Lumpur, Malaysia

Adel Mahmoud
Senior Molecular Biologist, Princeton University, Princeton, New Jersey, United States

Anthony Measham
World Bank (retired)
Carol Medlin
Children’s Investment Fund Foundation, London, United Kingdom

Alvaro Moncayo
Researcher, Universidad de los Andes, Bogotá, Colombia

Jaime Montoya
Executive Director, Philippine Council for Health Research and Development, Taguig City, the Philippines

Ole Norheim
Professor, University of Bergen, Bergen, Norway

Folashade Omokhodion
Professor, University College Hospital, Ibadan, Nigeria

Toby Ord
President, Giving What We Can, Oxford, United Kingdom

K. Srinath Reddy
President, Public Health Foundation of India, New Delhi, India

Sevkat Ruacan
Dean, Koc University School of Medicine, Istanbul, Turkey

Jaime Sepúlveda
Executive Director, Global Health Sciences, University of California, San Francisco, California, United States

Richard Skolnik
Lecturer, Health Policy Department, Yale School of Public Health, New Haven, Connecticut, United States

Stephen Tollman
Professor, University of Witwatersrand, Johannesburg, South Africa

Jürgen Unutzer
Professor, Department of Psychiatry, University of Washington, Seattle, Washington, United States

Damian Walker
Senior Program Officer, Bill & Melinda Gates Foundation, Seattle, Washington, United States

Ngaire Woods
Director, Global Economic Governance Program, Oxford University, Oxford, United Kingdom

Nopadol Wora-Urai
Professor, Department of Surgery, Phramongkutklao Hospital, Bangkok, Thailand

Kun Zhao
Researcher, China National Health Development Research Center, Beijing, China
Reviewers

Nicolas Andre, MD, PhD
Pediatric Oncology, Children’s Hospital of La Timone, AP-HM Marseille, France

Ronald D. Barr, MD
Professor of Pediatrics, Pathology, and Medicine, McMaster University, Hamilton, Ontario, Canada

Nazmi Bilir, MD
Professor of Public Health, Faculty of Medicine, Hacettepe University, Ankara, Turkey

Miguela A. Caniza, MD
Associate Member, Director of Infectious Diseases, International Outreach, Department of Infectious Diseases, International Outreach Program, St. Jude Children’s Research Hospital, Memphis, Tennessee, United States

Phaik-Leng Cheah, MBBS, MRC Path, FRC Path, MPath, MD
Professor, Department of Pathology, Faculty of Medicine, University of Malaya, Kuala Lumpur, Malaysia

Maria Paula Curado, MD, PhD
Senior Researcher, International Prevention Research Institute, and Epidemiologist, Accamargo Cancer Center, International Research Center, Sao Paulo, Brasil

Henry Ddungu, MD, consultant
Uganda Cancer Institute, Kampala, Uganda

Nagi S. El Saghir, MD, FACP
Professor of Clinical Medicine, Director, Breast Center of Excellence, NK Basile Cancer Institute, Division of Hematology/Oncology, Department of Internal Medicine, American University of Beirut Medical Center, Beirut, Lebanon

Dan Greenberg, PhD
Associate Professor and Chairman, Department of Health Systems Management, Guilford Glazer Faculty of Business Management & Faculty of Health Sciences, Ben-Gurion University of the Negev, Beersheba, Israel

Raymond Hutubessy, PhD
Senior Health Economist, Initiative for Vaccine Research, World Health Organization, Geneva, Switzerland

M. Tezer Kutluk, MD, PhD
Professor of Pediatrics and Pediatric Oncologist, Hacettepe University Cancer Institute, Ankara, Turkey

Cédric Mahé, PhD
Senior Director, Global Epidemiology, Sanofi Pasteur, Lyon, France

Donald Maxwell Parkin, MD, PhD
Senior Epidemiologist, Centre for Cancer Prevention, Wolfson Institute of Preventive Medicine, Queen Mary University of London, London, United Kingdom

Aloka Pathirana MS, FRCS (Eng), FRCS (Edin)
Professor in Surgery, University of Sri Jayawardenepura, Nugegoda, Sri Lanka

Sevket Ruacan, MD
Professor of Pathology, Koc University School of Medicine, Istanbul, Turkey

Vikash Sewram, PhD (Medicine, Chemistry, and Physiology), MPH (Cancer Epidemiology), PhD (Public Health)
Director, African Cancer Institute, Stellenbosch University, Stellenbosch, South Africa
Frank A. Sloan, PhD  
J. Alexander McMahon Professor of Health Policy and Management and Professor of Economics, Duke University, Durham, North Carolina, United States

Verna Dnk Vanderpuye, MBCHB, FWACS  
Consultant Radiation and Clinical Oncologist, Department of Radiation Oncology, Korle Bu Teaching Hospital, Accra, Ghana

Katsuri Warnakulasuriya, Oral Med BDS, FDSRCS, PhD, Dip, DSc  
Professor of Oral Medicine and Experimental Oral Pathology, King’s College London, London, United Kingdom

Sidney J. Winawer, MD  
Paul Sherlock Chair in Medicine, Gastroenterology and Nutrition Service, Department of Medicine, Memorial Sloan-Kettering Cancer Center; Professor of Medicine, Weill Medical College, Cornell University, Ithaca, New York, United States

Cheng-Har Yip, MBBS, FRCSEd, FRCS  
Consultant breast surgeon, Breast Centre, Sime Darby Medical Centre, Selangor, Malaysia
Index

Boxes, figures, maps, notes, and tables are indicated by b, f, m, n, and t respectively.

A
abandonment of therapy
  for breast cancer, 266, 292
  for childhood cancer, 124, 125, 125b, 126–27b, 127, 130, 205, 205b, 291
  due to expense, 282
Abascal, W., 189
accreditation programs, 125, 195, 199, 200, 203, 207n10, 244
acute lymphoblastic leukemia (ALL). See leukemia
acute promyelocytic leukemia (APL), 126b
ADA (American Dental Association), 91
Adami, H., 215
Adewole, Isaac F., 223
adjuvant treatment considerations for surgery, 230–31
advertising of cigarettes, 185, 189
affordability of cancer services, 15. See also catastrophic health expenditures
  abandonment of therapy due to inability to afford, 127
  anti-HBV drugs, 158
  anti-HCV drugs, 156
Afghanistan, radiation therapy in, 265
aflatoxins, 11, 150, 151, 153, 156–57, 159
Africa. See also specific regions and countries
cervical cancer prevention approaches in, 80
types of cancer in, 29
AHOPCA (Central American Association of Pediatric Hematology Oncology), 130
air pollution, 12, 38
alcohol consumption
  binge drinking, 157
  liver cancer and, 153–54, 157
oral cancer and, 85, 87, 89
  as risk factor, 37
Algeria, cervical cancer in, 71
ALL (acute lymphoblastic leukemia). See leukemia
Amarasinghe, Hemantha, 85
American Board of Internal Medicine's Choosing Wisely campaign, 212
American Cancer Society Cancer Prevention Studies, 254
American Dental Association (ADA), 91
American Pain Society, 166
American Society of Clinical Oncology, 111, 212
AMPATH Program (U.S.), 245
Anderson, Benjamin O., 45, 216, 223, 263, 268
anesthesia, administration of, 137–38, 224, 226
Antillon, Federico G., 121
antiretroviral therapy, 73, 156
antiviral therapy for HBV and HCV, 155–56, 158, 159, 160
APL (acute promyelocytic leukemia), 126b
areca nut. See nut chewing
Argentina
  colorectal cancer in, 11, 108
  tobacco control, compared to Uruguay, 189
  aromatase inhibitor (AI), 12b, 54, 60
  asbestos exposure, 12, 38
Asia. See also specific regions and countries
  breast cancer in, 216
  cervical cancer in, 71, 71m
  childhood cancer in, 121
  health insurance coverage in, 289
  liver cancer in, 147, 150
  oral cancer in, 85, 87
  types of cancer in, 29
Asian Development Bank, 188
Asma, Samira, 175
Atun, Rifat, 281, 284
Australia/New Zealand
cancer registries in, 266
cigarettes in
plain packaging of, 185, 189
tax rates, 184
cost-effectiveness study in, 267
lung cancer in, 177
oral cancer in, 88
reporting system for HPV infection and vaccinations in, 258
Austria, cervical cancer screening in, 74
Axios Healthcare Development, 78

B
Badwe, Rajendra A., 223
Baltussen, R. M., 59, 216
Bamako Global Ministerial Forum on Research in Health (2008), 249
Call to Action for Research on Health, 249, 250b, 256
Bangladesh
cervical cancer in, 71, 74
costs of cancer treatments in, 7, 236
smoking in, 178, 180
Belarus, oral cancer in, 85
benefits of cancer control, 17. See also cost-effectiveness “best buys”
in cancer services, 8
in research, 259–60
betel nut. See nut chewing, as oral cancer risk
bevacizumab, 13
Bhakta, N., 138–39
BHGI. See Breast Health Global Initiative
Bhutan, HPV vaccination in, 78
Bill & Melinda Gates Foundation, 189
binge drinking, 157
biobanks and biological resource centers, 252–53
biopsy procedures, 54, 63, 227–28. See also
tissue sampling
biostatisticians, 257
bladder cancer
radiation therapy for, 240
schistosomiasis and, 12
blood donations/transfusions and HCV risk,
153, 155, 158
Bloomberg Philanthropies, 189
Bolivia, HPV vaccination in, 78
bone marrow transplantation, 129, 197b, 204, 240
B. P. Koirala Memorial Cancer Hospital (Nepal), 206b
brachytherapy, 241
brain cancer
incidence and death rates, 28f
radiation therapy for, 240
underdiagnosis of childhood brain tumors, 121
Bray, Freddie, 23
Brazil
breast cancer treatment in, 60
childhood cancer in
cost-effectiveness of treatment, 139
mortality rates, 123
treatment, 127b
colorectal cancer incidence rates in, 103
costs of intervention packages in, 13, 277
oral cancer in, 85
percent of total health spending to cancer control in, 15
radiation therapy in, 245
smoking in, 180
knowledge of health information, 184
tobacco use in, 10
breast cancer, 45–68. See also Breast Health Global Initiative
abandonment of therapy, 266, 292
access to diagnostic and treatment facilities, 225
assessment of local situation, 57–59
social and cultural barriers, 58
target group identification, 58–59
breast awareness education, 50, 52, 215
breast self-examination, 52, 216
chemotherapy, 11, 12b, 54–55, 55–56, 275
clinical breast examination (CBE), 51–52, 60, 63,
215–16, 235, 266, 277
clinical evaluation, 53–54
clinic-based cluster randomized trial, 62–63
combination screening-treatment interventions,
60–61
comparison of modalities, 61
cost-effectiveness of interventions, 13, 13f, 59–61,
268, 269–70t
dedicated cancer center (Egypt), 206b
diagnosis, treatment, and patient triage, 63
diagnosis guidelines, 53–54, 53t
diagnostic imaging, 54
disparities in global outcomes, 45–47
eyear-stage treatment of, 8, 11, 29, 60
cost-effectiveness of, 13, 13f
costs of, 14t
early detection, 45, 47, 49, 50t, 60
in LMICs, 12b
scaling up, 16
economic analyses and future of breast health care in LMICs, 63–64
estrogen receptor protein, testing for, 11, 12b
field studies, 61–63
by geographical region, 29
high-risk screening, 212
incidence and death rates, 6t, 8f, 27–29, 28f, 45, 46m, 215
disproportionate death rates of the young, 45
by income group, 31f, 47–48f, 224f
transitions in low- and middle-income countries, 29–32
intervention packages, 9t
literature review, 59–60
mammographic screening. See mammograms
overdiagnosis concerns, 213, 215
population-based randomized trial, 62
radiation therapy for, 11, 54, 55–56t, 60, 240
rate of curing, 4b
resource limitations, need for guidelines to address, 48–49
risk factors and risk reduction strategies, 47–48
screening for, 10–11, 212, 215–16
cost-effectiveness of, 13f
gender inequity as issue, 214
HIV-positive women, 219
maternal or reproductive health policy as umbrella for, 219
priority in LMICs, 218
surgery, 54, 223, 226, 228, 229t, 230
survivor groups, formation of, 58, 58f
systemic pharmacotherapy, 54–57
temporal trends in stage of disease, 61–62
tissue sampling, 54, 63
treatment guidelines, 54–57, 55–56t
tumor markers, 54
Breast Health Global Initiative (BHGI)
design of, 48–49
early detection guidelines, 49–57, 50t
effectiveness of, 267
evidence-based, resource-stratified approach, 216
Ghana-Norway partnership as part of, 199
guidelines developed by, 12b, 198, 218
implementation, 57–59
resource levels, 49b, 263–64
Brethauer, M., 215
British doctors, cohort study of, 254
British Royal College of Physicians, 185
burden of cancer, 23–44. See also specific types of cancer
alcohol consumption and, 37
asbestos exposure and, 38
compared to other noncommunicable diseases, 24, 24f
diet and, 37–38
diversity of cancer by type and geographical region, 29
environmental factors, 38
hormonal and reproductive factors, 38
HPVs and hepatitis B and C viruses and, 36–37
by income group, 27–29, 31, 31–35f
infections, cancers associated with, 36–37, 37f
tobacco-related cancer, 32, 34–36
transitions of various types of cancers, 23, 29–32
Burkitt, Denis, 134
Burkitt lymphoma, 11, 123, 129t, 134–37, 136t
Cambodia
cervical cancer in, 71
HPV vaccination in, 78
liver fluke infection in, 154
Cameroon
costs of cancer treatments in, 7, 236
HPV vaccination in, 78
Canada
Canadian National Breast Screening Study, 215
Cancer Care Ontario’s Program in Evidence-Based Care, 198
childhood leukemia in, 122
colorectal screening program (ColonCancerCheck) in, 108
liver cancer, cost of treatment in, 159
radiation therapy in, 245
smoking in
excise tax increases, 184
inverse relationship of consumption and price, 183, 183f
smuggling and black market sales of cigarettes, 187
taxation to finance universal health coverage in, 284
Victoria Hospice (Victoria, British Columbia), 206b
cancer awareness
breast awareness education, 50t, 52, 215
cultural practices and, 225
public awareness of, 16, 255
Cancer Care Ontario’s Program in Evidence-Based Care, 198

cancer death rates. See also specific types of cancer
decreases (2000 to 2010), 6, 8t, 17
in high-income countries (HICs), 2–3m, 6t, 8f
as key indicator of burden of cancer, 25–26
in low- and middle-income countries (LMICs), 2–3m, 6t, 8f
projected (2030), 9t, 17, 245
by region, 27f
cancer incidence. See also specific types of cancer
as key indicator of burden of cancer, 25, 27f
most common cancers by gender, 30m
projected (2030), 36f
registries compiling information on, 251
*Cancer Incidence in Five Continents* (IARC), 25, 57, 266
*Cancer Intervention and Surveillance Modeling Network* (CISNET), 111
cancer registries. See registries
cancer research. See research support
cancer screening, 211–22. See also specific types of cancer
care pathway for positive results, development of, 214
cost-effectiveness of, 214, 275–76
criteria for, 213
diagonal approach to, 218–19
effectiveness of, 10–11, 275–76
ethical considerations, 214–15
false-positive screening tests, 213
follow-up strategies, 214
high-risk screening, 212
infrastructure, education, and advocacy, 213–14
innovation, role of, 218
lead-time bias and, 212
length bias and, 213
opportunistic vs. organized screening, 108, 211–12,
266, 277
organized screening requirements, 108, 213–15
overdiagnosis concerns, 213, 215
overview, 211
policy considerations, 219
population-based screening, 212
priorities in LMICs, 218
structural obstacles to, 214
target age range of, 212
Wilson-Junger criteria for, 213, 213b
cancer services for comprehensive cancer center. See comprehensive cancer centers
cancer surveillance systems. See surveillance systems
cancer survival rates, 291. See also specific types of cancer
in high-income countries (HICs), 1, 6t
in low- and middle-income countries (LMICs), 6t
Canfell, K. H., 296
capacity building. See also scaling up
radiation therapy and, 275
research support and, 250b
surgery and, 232–35, 275
case-control studies, 253
catastrophic health expenditures, 7, 282, 284, 290
Centers for Disease Control and Prevention (U.S.), 252
Central American Association of Pediatric Hematology Oncology (AHOPCA), 130
Central Asia
alcohol consumption in, 157
cervical cancer in, 69
HPV vaccination in, 79
liver cancer in, 149
Central Europe
colorectal cancer in, 102
liver cancer in, 149
oral cancer in, 88
cervical cancer, 69–84
burden of, 69–71, 216, 295, 300–301
global, 69, 70f
regional, 71, 71m, 72f
chemotherapy, 11, 78, 275
cost-effectiveness of interventions, 8, 13, 78–79, 81,
217, 268, 271f
cytology classification and terminology, 72–73,
297–98
eye-stage treatment of, 8, 11
scaling up, 16
epidemiology and biology research, 257
by geographical region, 29
HIV and, 73, 219
HPV infection, integrated research on link to,
257–59, 258–59b. See also HPV (human papillomavirus) infection
HPV vaccination programs for. See HPV (human papillomavirus) vaccination
incidence and death rates, 6t, 8f, 27–29, 28f, 69,
215, 216
by income group, 34f, 72f, 224f
median age at death, 71
trends in, 29
integrated research exemplar, 257–59
natural history of, 72
overview, 69
Pap smears and, 69, 73, 74, 216
radiation therapy for, 11, 78, 240
rate of curing, 4b
research support for, 259–60
screening for, 10, 69, 73–77, 74t, 216–17
case study of upscaling VIA, 75
combined HPV vaccination and screening,
80–81, 217
cost-effectiveness of, 80
cryotherapy (screen-and-treat approach), 217
gender inequity as issue, 214
HIV-positive women, 219
HPV testing, 75–77
maternal or reproductive health policy as umbrella for, 219
priority in LMICs, 218
self-collection by women, 76
target age for, 212
triage of positive HPV tests, 76–77
visual inspection with acetic acid (VIA), 74–75, 217, 266, 277, 297–98
surgery, 228, 229
treatment of, 9

cetuximab, 13
Chaloupka, Frank. J., 175
Chao, Ann, 249
chemotherapy
breast cancer, 11, 12b, 54–55, 55–56t, 275
Burkitt lymphoma, 135–37
cervical cancer, 11, 78, 275
cancer, 124, 125t, 126, 128, 129t
colorectal cancer, 110, 111, 112, 114, 275
comprehensive cancer center services, 200, 231
in conjunction with radiation therapy, 240, 243
in conjunction with surgery, 231
health insurance coverage and, 290
Hodgkin lymphoma, 131–32, 132t
oral cancer, 94, 275
retinoblastoma, 138
scaling up, 16, 275
Wilms tumor, 133–34
Chen, Chien-Jen, 147
Chen, Wendong, 147
Chennai Prospective Study, 254
childhood cancer, 121–46. See also leukemia
abandonment of therapy, 124, 125, 125t, 126–27b, 127, 127b, 130, 205, 205b, 291
achievement of cure, 123
burden in LMICs of, 121–23
Burkitt lymphoma, 11, 123, 129t, 134–37, 136f
cancer of most common childhood cancers, 129t
chemotherapy, 124, 125t, 126, 128, 129t
cost-effectiveness of interventions, 13, 13f, 138–40, 139–40f, 268, 275–76t, 277
costs of interventions, 14f
future directions for progress, 140
in HICs, 121, 126
Hodgkin lymphoma, 129t, 131–33, 132f, 240
incidence rates, 121
inclusion in cancer registries, 121, 122f
ineffectiveness of prevention and screening, 123
International Incidence of Childhood Cancer (IARC), 123
in LMICs, 123, 125t, 127, 128, 139
locally adapted treatment protocols, 126–27, 139
Mexican national health insurance coverage of, 1
mortality rates, 123
outcome evaluation, 127–28
rate of curing, 4b
retinoblastoma, 137–38
scaling up, 277
spillover effect from pediatric to adult oncology, 123
treatment of, 11, 123–25
dedicated centers, 123–24, 124t, 128
infrastructure needed in LMICs, 125t
principles of, 126–28
specific cancers, 128–38
treatment facilities, organization of, 9t, 16, 125t
twinning programs, 124–25, 130, 140, 266
underdiagnosis of childhood brain tumors, 121
Wilms tumor, 11, 126, 133–34, 133t, 135t
Children’s Oncology Group in North America, 133
Chile
opioids for pain relief in, 169
training of health care professionals in, 204
China
air pollution in, 38
breast cancer in, 52, 60
cervical cancer in
burden of, 301
screening program, 295–96
childhood cancer treatment in, 125
acute lymphoblastic leukemia (ALL), 128, 130–31
chronic lung disease in, 178
colorectal cancer in, 103, 111
cost-effectiveness of HPV vaccination in, 295–305.
See also HPV vaccination
costs of intervention packages in, 277
dietary changes in, 150, 156
HBV infection in, 151
HBV vaccination in, 150, 155, 158
HCV infection in, 151
HPV vaccination in, 295–305. See also HPV vaccination
liver cancer in, 149, 150
liver fluke infection in, 154
national health insurance in, 284, 285t, 289, 290, 292
cancer surgery coverage, 7
costs, 291
fee-for-service basis, 292
opioid accessibility in, 170
oral cancer in, 88, 94
percent of total health spending to cancer control in, 15
smoking in, 179, 180
affordability, 182
implications of tobacco taxation, 188
knowledge of health information, 184
male smoking prevalence, 30, 35, 177
price elasticity, 181
related cancer deaths in, 177
starting age of men, 178
stomach cancer in, 218
types of cancer in, 29
China Kadoorie Biobank, 254, 255b
chronic lung disease, 178
chronic trauma, as risk factor for oral cancer, 90
CISNET (Cancer Intervention and Surveillance Modeling Network), 111
Cleary, James, 165
clinical breast examination. See breast cancer
Clinton Health Access Initiative, 16
Clonorchis sinensis, 36
Cochrane Collaboration, 91
codexine, 165, 166, 168
cohort studies, 254, 254–55b
Colombia
breast cancer in, 62
childhood cancer in, 16
universal health care in, 284, 285t
cancer coverage, 290, 291
incentives to improve coverage, 292
colonoscopy, 106–7, 217
colorectal cancer (CRC), 101–19
burden of, 101–5, 217
chemotherapy, 110, 111, 112, 114, 275
cost-effectiveness of interventions, 7b, 13, 13f, 114, 217, 268, 272–73t
diagnosis of, 109
diet, lifestyle, and medications as risk factors for, 105, 114, 217
European Guidelines for Quality Assurance in Colorectal Cancer Screening and Diagnosis (IARC), 107, 108
genetic factors, 105
high-income countries recommendations, 116
high-risk screening, 212
incidence and death rates, 6t, 8f, 27–29, 28f, 101–5
by gender, 102m, 103–4f, 215
by income group, 33f, 103–5, 105f, 224f
transitions in low- and middle-income countries, 29
trends, 102–3
intervention packages, 9t
low-income countries recommendations, 114
middle-income countries recommendations, 115
overview, 101
physical inactivity, relationship to, 38
radiation therapy for, 110
recommendations, 114–16, 115t
research support for, 260
risk factors, 105
screening for, 11, 101, 105–9, 217
ColonCancerCheck (Canadian program), 108
colonoscopy, 106–7, 217
cost-effectiveness of, 11, 111–14
decal DNA, 106
decal immunochemical test (FIT), 105–6, 277
flexible sigmoidoscopy (FS), 106
guaiac decal occult blood test (gFOBT), 105, 108
high-risk screening, 212
IARC guidelines, 107, 108–9
ICRCN pilot program, 108
International Cancer Screening Network, 109
International Digestive Cancer Alliance, 109
organized vs. opportunistic screening, 108
performance of organized screening programs, 108
USMSTF guidelines, 108
USPSTF guidelines, 107–8
World Endoscopy Organization, 109
staging of, 109–10
barium enema, 109
cost-effectiveness of, 11, 111–14
colonoscopy, 106–7, 217
cost-effectiveness of, 11, 111–14
decal DNA, 106
decal immunochemical test (FIT), 105–6, 277
flexible sigmoidoscopy (FS), 106
guaiac decal occult blood test (gFOBT), 105, 108
high-risk screening, 212
IARC guidelines, 107, 108–9
ICRCN pilot program, 108
International Cancer Screening Network, 109
International Digestive Cancer Alliance, 109
organized vs. opportunistic screening, 108
performance of organized screening programs, 108
USMSTF guidelines, 108
USPSTF guidelines, 107–8
World Endoscopy Organization, 109
staging of, 109–10
barium enema, 109
cost-effectiveness of, 11, 111–14
colonoscopy, 106–7, 217
cost-effectiveness of, 11, 111–14
decal DNA, 106
decal immunochemical test (FIT), 105–6, 277
flexible sigmoidoscopy (FS), 106
guaiac decal occult blood test (gFOBT), 105, 108
high-risk screening, 212
IARC guidelines, 107, 108–9
ICRCN pilot program, 108
International Cancer Screening Network, 109
International Digestive Cancer Alliance, 109
organized vs. opportunistic screening, 108
performance of organized screening programs, 108
USMSTF guidelines, 108
USPSTF guidelines, 107–8
World Endoscopy Organization, 109
Commission on Macroeconomics and Health, 7b
community health centers, 226–27, 228–30t
community health workers, 200, 201, 256, 290
community involvement, 214
comprehensive cancer centers, 195–210
additional key supports, 202
administration and management, 201
affordability and domestic financing of, 15
cancer system components, 195–96, 196f
cancer system planning, 195
chemotherapy, 200, 231
clinical management, 197–98, 198f
clinical practice guidelines, 197–98
patient care plans, 197
clinical services, 198–200, 198f  
core services, 198f, 200–202  
financial systems, 202  
framework, 197–202, 198f  
global health, contribution to, 204–5  
heat resources, 201  
infection control, 201–2, 207n9  
information technology and management, 201 in LMICs, 196  
medical imaging (diagnostic radiology), 199  
office- and clinic-based ambulatory care, 199  
palliative care, 200  
pathology and laboratory medicine, 199  
pharmacy services, 201  
psychosocial support, 200  
quality assurance, 202  
quality of care with minimal resources, 202–5  
accessibility, 202  
catalyzing development of national systems, 203  
effectiveness, 202  
efficiency, 203  
equity, 202  
responsiveness, 202  
safety, 202  
radiation therapy, 199–200, 243  
regional cancer centers, establishment of, 203  
role in support of development of effective health care systems, 204  
supportive care, 200  
surgery, 199, 232  
surivorship programs, 200  
systemic cancer therapy, 200  
training of health care professionals, 203–4  
Congo, Democratic Republic of, liver cancer in, 149  
co-payments, 291  
cost-effectiveness, 13, 13f, 267–69. See also specific types of cancer  
cancer screening, 214, 275–76  
estimates of, 7b  
HPV vaccination, cost-effectiveness in China, 295–305. See also HPV (human papillomavirus) vaccination  
methods, 267–68  
results based on level of resources, 268–69, 268t  
studies of, 263, 267  
surgery, 235–36  
costs. See also affordability of cancer services; financing; specific types of cancer of cancer drugs, 12b  
catastrophic health expenditures, 7, 282, 284, 290  
DCP3 analysis of, 5b  
of interventions, 4b, 7b, 13–14, 14r, 277  
priority of reduction for essential intervention packages, 16  
of surgery, 235–36  
Council of Europe, 168  
CRC. See colorectal cancer  
Cuba, oral cancer in, 92, 94  
cultural practices  
  breast cancer and, 58  
cancer awareness and, 225  
cancer screening and, 214  
cervical cancer and, 71  
fatalism and, 225  
surgery and, 225  
Cure4Kids, 125  
customs reform to allow for importation of health research components, 253, 256  
cytosine, 186  
cytotoxic regimens, 12b  
Czech Republic, oral cancer in, 87  
D  
Dare, Anna J., 223  
D’Cruz, Anil, 195  
death certificates, indicating smoking habits of deceased, 185  
death rates. See also cancer death rates  
top 10 causes of death worldwide, 24, 24f  
death registration systems, linking to cancer registration systems, 253. See also registries  
delayed presentation for cancer as norm in LMICs, 213–14, 234, 282, 290  
Democratic Republic of Congo, liver cancer in, 149  
Denny, Lynette, 69, 268  
diagnosis and staging, 11. See also specific types of cancer  
role of laboratories and anatomic pathology, 252  
surgery’s diagnostic role, 227  
UICC Tumor, Nodes, Metastasis (TNM) staging system, 92  
diagnostic imaging  
  breast cancer, 54  
  comprehensive cancer center services, 199  
  follow-up to positive screening test with, 214  
  oral cancer and, 92  
surgery’s reliance on, 226  
diet, relationship to cancer, 37–38  
  colorectal cancer, 105  
  liver cancer, 150, 156  
digital mammography, 51  
Dikshit, R., 253  
disability-adjusted life years (DALYs)  
  cervical cancer and, 71, 216
cost-effectiveness and DALYs averted, 13, 214
liver cancer and, 150

disease control priorities
HPV (human papillomavirus) vaccination in
essential package of, 8
publication background of, 5b

dNA testing for HPV. See HPV (human
papillomavirus) infection

doll, richard, 176

dominican republic
childhood cancer treatment in, 130
universal health care in, 284, 286, 289
drug costs. See affordability of cancer services
drug therapy. See also chemotherapy; pain relief
breast cancer, 55–56, 55–57
comprehensive cancer centers, 201
constraints on, 265
as risk factor, 105
smoking cessation treatment, 186
universal health care, coverage of, 290

dutch childhood oncology group, 130–31

E
earle, craig, 101
east asia and pacific
aflatoxins in, 153
HBV infection in, 151
HCV infection in, 155
liver cancer in, 147, 149
stomach cancer in, 218

eastern europe
colonial cancer in, 102
oral cancer in, 85, 87
types of cancer in, 29
e-cigarettes, 186
egypt
breast cancer in, 206b
cervical cancer in, 71
fakous cancer center, 206b
HCV infection in, 151, 153
incidence of HBV vs. HCV in, 151, 152f
liver cancer in, 149
National cancer institute, 206b
dermocrine therapy, 54–55, 55–56
environmental factors, 38
epidemiologic studies, 253–57, 260
epstein-barr virus, 36, 131
 Ergo, A., 283
erthyroplakia, 90
esophagus. See oral cancer
estrogen receptor protein, testing for, 11, 12b, 45
ethical considerations of cancer screening, 214–15

ethiopia

European guidelines for quality assurance in colorectal
cancer screening and diagnosis (IARC), 107, 108, 109
European medicines agency, 258
Europe/european union. See also specific regions
and countries
alcohol consumption in, 157
cancer registries in, 266
cervical cancer in, 69
HPV vaccination in, 79
liver cancer in, 150
lung cancer in, 177
radiation therapy in, 244
smoking in, 180

F
fakous cancer center (egypt), 206b
false-positive screening tests, 213
farming practices. See aflatoxins
FCTC (framework convention on tobacco control),
10, 89, 188, 189
fee-for-service payments, 292
fentanyl patch, 168, 169, 170
Ferlay, J., 25
financing, 281–94. See also health insurance
cancer care and, 15, 282–83
country approaches, 283
domestic funding, 282
need for financial protection, 282
out-of-pocket spending by families, 282, 290
overview, 281–82
progressive universalism, 283
public financing, 282, 290–91
research support and, 256
surgery and, 235–36
Finland, ban on advertising of cigarettes in, 185
first-level hospitals
intervention packages, 9t
surgery in, 227, 228t
flukes. See liver fluke infection
Foley, K. M., 166
Fonseca, M., 60
Food and drug administration (U.S.), 258
food and grain storage. See aflatoxins
Framework convention on tobacco control (FCTC),
10, 89, 188, 189
France
HCV treatment in, 156
liver cancer in, 149
oral cancer in, 85
smoking in
  cigarette taxes, 10, 184
  inverse relationship of consumption and price, 183, 183f
  restrictions in public places, 185
Franceschi, Silvia, 147
Fred Hutchinson Cancer Research Center (Seattle, Washington), 205b
Frenk, J., 214

G
Gakidou, E., 74
Gambia, liver cancer in, 149
Gardasil Access Program, 78
gastric cancer. See stomach cancer
Gauvreau, Cindy L., 1, 223, 263
Gavi (The Vaccine Alliance), 10, 16, 36, 78–80, 155, 299
Gelband, Hellen, 1, 147, 165, 268, 281
gender differences
  cancer incidence and mortality by geographical region, 29, 215
  delay in screening for women, 214
  liver cancer, 148m, 149
  lung cancer, 29
  most common cancers by gender, 30m, 215
  oral cancer, 86t, 87–88m
  smoking and associated cancer risks, 35–36, 176, 177f, 180
genetic factors
  colorectal cancer, 105
  high-risk screening and, 212
  liver cancer, 149
  oral cancer, 89–90
  retinoblastoma, 137
Georgia, opioid accessibility in, 169
Germany
  opioid accessibility in, 170
  smoking restrictions in public places in, 185
Ghana
  breast cancer screening in, 290
  cervical screening in, 217
  Ghana-Norway partnership as part of Breast Health Global Initiative, 199
  HPV vaccination in, 78
  liver cancer in, 149
  universal health care in, 284, 286t, 289, 290
  taxes to finance, 292
Ginsburg, Ophira M., 211
GlaxoSmithKline, 299
Global Adult Tobacco Survey, 180, 182, 184
Global Fund for AIDS, TB and Malaria, 16
Global Initiative for Cancer Registry Development, 39

Globalization
  comprehensive cancer centers, contribution to, 204–5
  initiatives for cancer control, 16–17
  tobacco use and, 189
Global Monitoring Framework for Noncommunicable Diseases (WHO), 166
Global Opioid Policy Initiative (GOPI), 168, 170–71
Global Task Force on Expanded Access to Cancer Care and Control, 218–19
Global Task Force on Radiotherapy for Cancer Control, 16
Global Youth Tobacco Survey, 182
Goldie, S. J., 80, 296
Gospodarowicz, Mary K., 195, 239
Greenberg, D., 111, 267
Gross, Thomas, 249
Guatemala
  childhood cancer treatment in, 127b, 130, 197
  Unidad Nacional de Oncología Pediátrica (UNOP), 140
  opioid accessibility in, 170
Guinea
  cervical cancer in, 71
  liver cancer in, 149
Guinea-Bissau, liver cancer in, 149
Gupta, Prakash C., 175
Gupta, Sumit, 121, 205
Guyana, cervical cancer in, 71
Gwatkin, D. R., 283

H
Haiti
  domestic funding in, 282
  HPV vaccination in, 78
Hall, Andrew, 147
Harif, Mhamed, 121
HBV. See hepatitis B and C viruses
HCC (hepatocellular carcinoma). See liver cancer
HCV. See hepatitis B and C viruses
HDI (Human Development Index), 31, 71, 81n2, 166, 226
HDV (hepatitis D virus), 149
head and neck cancers
  imaging techniques for, 198
  radiation therapy for, 240
health care professionals
  research support role of, 250, 251b
  screening by community care workers and nurses, 218
  shortage of skilled medical personnel, 232–33, 266
  training of, 203–4
health communications, 255
health insurance
as constraint, 266, 282
coverage by population group, 284, 289
fee-for-service basis, 292
incentives, 292
results of coverage, 291–92
Seguro Popular (Mexico), 1, 125, 204, 266, 283, 284, 287, 291
services and conditions covered, 289–90
universal health coverage of cancer services, 4b, 234, 281, 283, 284, 289
Health Insurance Plan of Greater New York, 51
health surveillance systems. See surveillance systems
heart attack, smoking’s relationship to, 178, 185, 187
hepatitis B (HBV) and C (HCV) viruses, 154–56
antiviral therapy for, 155–56, 158, 159, 160
burden of cancer linked to, 36–37
liver cancer, 149–53
communication about, 255
incidence of HBV vs. HCV in, 151, 152f
prevention of HCV, 156b
screening for, 155–56
treatment of HBV, 155. See also hepatitis B vaccination
cost-effectiveness of, 158
treatment of HCV, 155–56
cost-effectiveness of, 158–59
hepatitis B (HBV) vaccination, 4b, 154–55
burden of cancer and, 36
communication about, 255
cost-effectiveness of, 8, 13, 13f, 158, 267
costs of, 14f
global coverage, 10, 147
plasma-derived vaccine, 15
scaling up, 15, 149
hepatitis D virus (HDV), 149
hepatocellular carcinoma (HCC). See liver cancer
herpes virus type 8, 36
Herrero, Rolando, 69
high-income countries (HICs)
advanced cancer treatment in, 12
breast cancer in, 45, 48, 215
Burkitt lymphoma in, 135
cancer death rates in, 2–3m, 6t, 8f, 24, 27–28, 165
cancer survival rates in, 1
cervical cancer in, 70f
childhood cancer in, 11, 121
colorectal cancer in, 101, 108, 116
cost-effectiveness of cancer interventions in, 7b, 268
HCV infection in, 155
high-risk screening for breast or ovarian cancer in, 212
liver cancer in, 150
lung cancer in, 29
palliative care in, 11, 167, 169
percent of total health spending to cancer control in, 15
prostate cancer in, 29
retinoblastoma in, 138
smoking in
advertising of cigarettes, ban on, 185
e-cigarettes, 186
health information and counter-advertising, 184–85
public places, restrictions on, 185
tobacco control, investment in, 189
tobacco excise taxes, 182–83
types of cancer prevalent in, 27
Hill, A., 156
HIV. See also antiretroviral therapy
cervical cancer and, 73
screening HIV-positive women for breast and cervical cancer, 219
Hodgkin lymphoma, 129f, 131–33, 132f, 240
Honduras
cervical cancer in, 71
childhood leukemia in, 16, 122, 197
Hong Kong SAR
colorectal cancer in, 111
oral cancer in, 88
smoking risks in, 178–79
hormonal and reproductive factors, 38
Horton, Susan, 1, 101, 263, 281
Hospice Africa Uganda, 168, 170
hospice-palliative care, 167
hospitals. See also comprehensive cancer centers
intervention packages, 9t
research role of, 250
surgery in, by hospital level, 227, 228f
upgrading, 16
households, impact on, 7–8. See also catastrophic health expenditures
Howard, Scott C., 121
HPV (human papillomavirus) infection
burden of cancer linked to, 36–37, 69, 71, 72, 282, 300–301
communication about, 255
DNA testing for, 233, 258, 266, 267
future research needs, 258–59, 258–59b
integrated research establishing link to cervical cancer, 257–59
oral cancer and, 87, 88, 90, 218
screening for, 10, 75–77, 212
in China, 296–97
HPV (human papillomavirus) vaccination
case studies of implementation, 78
combined HPV vaccination and screening, 80–81, 217
communication about, 255
cost-effectiveness in China, 295–305
  benefits and costs of publicly financed program, 299–301, 301t
  cost assumption, 303
  cost data sources, 299
  delay in approving HPV vaccines, 303
  extended cost-effectiveness analysis, 296–97
  limitations of analysis, 303
  model, 297, 298t
  policy reform to expand present Expanded Program for Immunization, 303
  results, 299–300, 302t
  sensitivity analysis, 299, 300–301t
  strategies, data, and assumptions, 297–98
  cost-effectiveness of, in China, 295–305. See also above: cost-effectiveness in China
costs of, 14t, 282
  in DCP3 Cancer essential package, 8
  efficacy, 4t, 77
  Gavi subsidy of, 36
  national programs, 10, 69
  public health challenges to implementing, 77
  scaling up, 15, 217
  universal health coverage of, 291
Human Development Index (HDI), 31, 71, 81n2, 166, 226
human immunodeficiency virus. See HIV
human rights, pain relief as, 165
Human Rights Watch, 168
human T-cell lymphotropic virus type 1, 36
Hungary, oral cancer in, 87, 88
Hunger, Stephen P., 121
I
IAHPC (International Association for Hospice and Palliative Care), 167, 170
IARC. See International Agency for Research on Cancer
ICRCSN (International Colorectal Cancer Screening Network), 108, 217
Ilbawi, Andre, 223
imaging. See diagnostic imaging
implementation science, 255–56
  as “best buy” for cancer research, 259
INCB (International Narcotics Control Board), 168
incidence. See cancer incidence; specific types of cancer
income as proxy for human development, 26
India
  acute lymphoblastic leukemia (ALL) in, 128
  breast cancer in, 45–47, 52, 226, 235
  Mumbai trial, 216, 218
cancer death rates in, 7
  cancer surgery costs in, 7
  cervical cancer in, 71, 217, 258
  childhood cancer in, 121, 122
  chronic lung disease in, 178
costs of intervention packages in, 13, 282
guidelines adapted to local resource availability in, 198
HBV infection rates in, 149
HBV vaccination in, 158
HCV treatment, cost-effectiveness of, 159
HPV testing and reduction in cervical cancer in, 258
liver cancer in, 149, 150
Million Death Study, 39
National Cancer Control Program, 203–4b
National Cancer Grid, 16, 231
opioid accessibility in, 168, 170
oral cancer in, 11, 85, 89, 92, 94, 95
percent of total health spending to cancer control in, 15
radiation therapy in, 245
regional cancer centers in, 203–4b
retinoblastoma in, 137
smoking in, 178, 180
  cigarette taxes, 10, 188
  knowledge of health information, 184–85
  related cancer deaths in, 178
surgery, private vs. public sector provision of services in, 234
tuberculosis in, 178
universal health care in, 284, 286t, 289, 290, 292
  cap on payments, 292
  co-payments, 291
Indonesia
  acute lymphoblastic leukemia (ALL) in, 128
  breast cancer detection in, 51
  childhood cancer treatment in, 127b
  smoking in, 180
    male smoking prevalence, 30
    WTO case on U.S. ban of clove-flavored cigarettes, 189
types of cancer in, 29
inequality in health, contribution of cancer control to reducing, 17
infections, cancers associated with, 36–37, 37f. See also HPV (human papillomavirus) infection
information technology and management, 201, 218
informed consent to mammographic screening, 51
injected drug administration and HCV infection, 151, 155, 156b
Institute for Health Metrics and Evaluation, 250
International Agency for Research on Cancer (IARC)
on alcohol as liver carcinogen, 153
Index

on breast self-examination, 52
Cancer Incidence in Five Continents, 25, 57, 266
on cervical cancer screening, 73
on clinical breast examination, 51
on colorectal cancer screening, 107, 108–9
estimating cancer incidence and death rate, 6
global initiative for cancer registry, 40, 40m
GLOBOCAN, 7b, 25, 27, 81n1, 297
International Incidence of Childhood Cancer, 123
on liver flukes, 154
on lung cancer in men in HICs, 177
on mammogram screenings, 50
Monographs on the Evaluation of Carcinogenic Risks to Humans, 12
national cancer mortality databank of, 26
radiation facilities provided to Sub-Saharan Africa by, 266
Working Group on Cervical Cancer Screening, 73
International Association for Hospice and Palliative Care (IAHPC), 167, 170
International Association of Cancer Registries, 25
International Atomic Energy Agency (IAEA), 199, 244
Programme of Action for Cancer Therapy, 245, 267
International Cancer Screening Network, 109, 267
International Childhood Cancer Cohort Consortium, 254
International Classification of Diseases, 25, 26
International Colorectal Cancer Screening Network (ICRCSN), 108, 217
International Digestive Cancer Alliance, 109
International Federation of Gynecology and Obstetrics, 78
International Narcotics Control Board (INCB), 168
International Network for Cancer Treatment and Research, 206b
International Observatory of End of Life Care, 167
international partnerships. See also twinning programs
colorectal cancer and, 111
effectiveness of, 266–67
research support, 257
International Society of Oncology Pharmacy Practitioners, 201
International Society of Pediatric Oncology (SIOP), 125
Abandonment of Treatment Working Group, 127
International Society of Radiology, 199
interventions. See also specific types of cancer
cost-effectiveness of, 4b, 7b, 13, 13f
diagnosis and treatment, 11
essential packages of, 8–13, 9f
implementation challenges for, 15–16
local priority conditions, 11–13
palliative care. See pain relief
prevention. See prevention strategies
resource requirements, 14, 14f
screening. See cancer screening surgery. See surgery
intestinal cancer. See stomach cancer
intravenous drug users, HCV infection in, 151, 155, 156b
Iran, opioid accessibility in, 170
Iraq, radiation therapy in, 265
Ireland
radiation therapy in, 245
smoking restrictions in public places in, 185
Israel, liver cancer in, 150
Israels, Trijn, 121
Italy
HCV infection in, 151
incidence of HBV vs. HCV in, 151, 152f
J
Jaffray, David A., 239
Jamaica
cervical cancer in, 71
opoid accessibility in, 169
Jamison, Dean T., 295
Japan
cancer death rates in, 24
quitting smoking’s effect on, 178
smoking’s effect on, 175–76, 177f
colorectal cancer screening in, 108
HCV infection in, 151
incidence of HBV vs. HCV in, 151, 152f
liver cancer in, 149
lung cancer in, 177
mammography in, 63
oral cancer in, 88
stomach cancer in, 218
Japan Life Span Study, 254
Jha, Prabhat, 1, 175
Johnson, Newell, 85
Jordan
childhood leukemia in, 122
King Hussein Cancer Foundation, 196, 196–97b
opoid accessibility in, 168
Kenya
HPV vaccination in, 78
opoid accessibility in, 168–69
radiation therapy in, 245
Khader, Jamal, 195

330 Index
Kim, Jane J., 69, 295
King Hussein Cancer Foundation (Jordan), 196, 196–97b
Knaul, Felicia, 195, 214, 281, 284
Korea, Republic of
breast cancer treatment in, 60
colorectal cancer in, 108, 111
fee-for-service payments in, 292
liver cancer in, 149
liver fluke infection in, 154
mammograms in, 60
oral cancer in, 88
stomach cancer in, 218
thyroid cancer in women in, 29

L
laboratories. See also pathology
in comprehensive cancer centers, 199
constraints, 265
research role of, 252
Ladner, J., 78
Lambert, R., 114, 217
Lan, N. H., 235
Lancet Commission on Investing in Health, 284
Lao People's Democratic Republic
HPV vaccination in, 78
liver cancer in, 149
liver fluke infection in, 154
larynx. See oral cancer
Latin America and the Caribbean. See also specific countries
aflatoxins in, 157
alcohol consumption in, 157
cervical cancer in, 71, 71m
health care coverage, variations in, 284, 289
liver cancer in, 149, 150
Network of National Cancer Institutions of Latin America (RINC) initiative, 245
oral cancer in, 85
radiation therapy in, 244
types of cancer in, 29
lead-time bias, 212
Lee, S., 60
length bias, 213
Lesotho, HPV vaccination in, 78
leukemia
acute lymphoblastic leukemia (ALL), 11, 127, 128–31
characteristics of, 129t
chemotherapy, 129–30
costs of treatment, 130–31, 290
diagnosis of, 129
in HICs, 128–29
in LMICs, 129–30
treatment of, 129–30
acute myeloid leukemia, 197
acute promyelocytic leukemia (APL), 126b
incidence and death rates, 6t, 28f
childhood, 121–23, 122f
radiation therapy for, 240
leukoplakia, 90
Levin, Carol, 69, 249, 295
Libya, cervical cancer in, 71
lifestyle
breast cancer and, 45, 47
cancer and, 23–24, 29, 32, 38
colorectal cancer and, 105, 114, 217
Lipscomb, Joseph, 45
liver cancer, 147–64
aflatoxins and, 11, 150, 151, 153, 156–57, 159
alcohol consumption and, 153–54, 157
cost-effectiveness of interventions, 13, 13f, 158–60, 268, 273–74t
costs of treating, 159–60
global burden of, 147–50
HCC (hepatocellular carcinoma) as most common type, 147
incidence and death rates, 6t, 8f, 27–29, 28f, 147–49, 148m
age-specific incidence, 149
by gender, 148m, 149, 215
by income groups, 149–50, 150f
trends, 150
liver fluke infection, 11–12, 149, 154, 157–58, 277
obesity and, 147, 154
prognosis and DALYs, 150, 158
research support for, 259–60
risk factors, 150–54, 160t. See also hepatitis B and C viruses
treatment of, 9t, 158, 160, 160t. See also hepatitis B vaccination
vaccination programs for, 32, 154–56. See also hepatitis B vaccination
London, W. Thomas, 147
low- and middle-income countries (LMICs)
air pollution in, 38
alcohol consumption in, 157. See also alcohol consumption
breast cancer in, 45, 215–16. See also breast cancer compared to HICs, 216
cost-effective interventions, 59–61
early-stage treatment, 12b
incidence and death rates, 27, 59
Burkitt lymphoma in, 134. See also Burkitt lymphoma
cancer incidence and death rates in, 2–3m, 4b,
6t, 8f, 17, 27, 165, 166. See also specific types of cancer
cancer screening priorities in, 218. See also cancer screening
cancer statistics, need to compile and monitor in, 24, 26, 39
cancer survival rates in, 1
cancer transition in, 29–32
cervical cancer in, 69, 70f. See also cervical cancer
regional burden, 71, 71m
screening programs, 75, 216–17
treatment, 78
childhood cancer in, 123. See also childhood cancer
colorectal cancer in, 108. See also colorectal cancer
comprehensive cancer centers in, 196. See also comprehensive cancer centers
cost-effectiveness of interventions in, 13, 13f,
267–69, 270, 275, 276–77t, 277. See also cost-effectiveness
costs of cancer control in, 4b, 14t. See also costs
delayed presentation for cancer as norm in, 213–14, 234, 282, 290
economic overview, 263–64. See also cost-effectiveness
financing cancer care in, 15, 281
HPV vaccination programs in, 10, 77. See also HPV vaccination
inadequate resources in, 264
intervention packages in, 9–10
laboratories in, 265
liver cancer in, 150. See also liver cancer
lung cancer in, 177. See also lung cancer
noncommunicable diseases, death rates in, 24, 24f
oral cancer in, 85, 89. See also oral cancer
cost-effectiveness assessments of preventing and screening, 94–96
future research needs, 96
pain control in, 166–71. See also pain relief
radiation therapy in, 239, 265. See also radiation therapy
retinoblastoma in, 137
See also surgery
tobacco use in, 23, 35–36. See also tobacco use
affordability and, 182
smoking cessation patterns, 180
Westernized lifestyle adopted in, 24, 29, 217
low-income countries (LICs). See low- and middle-income countries (LMICs)
lung cancer
air pollution and, 38
asbestos exposure and, 38
burden of, 29–30
gender differences, 29, 177–78, 215
by geographical region, 29, 177
incidence and death rates, 8f, 27–29, 28f, 215
by income group, 29
radiation therapy for, 240
Luo, X. Q., 131
Luxembourg, cervical cancer screening in, 74
lymphoma. See also Burkitt lymphoma; Hodgkin lymphoma
incidence and death rates, 28f
radiation therapy for, 240
M
MacLennan, Mary, 175
Madagascar
cervical cancer screening in, 75
HPV vaccination in, 78
Malawi
Burkitt lymphoma in, 137
cervical cancer in, 71, 75
childhood cancer in, 139
HPV vaccination in, 78
nonphysicians performing surgery in, 232
Malaysia
cervical cancer prevention approaches in, 80
liver fluke infection in, 154
referral hospital in, 61
mammograms, 10–11, 29, 45, 49–51, 51t, 57–58, 63, 212, 214, 215–16, 277, 290
mastectomy, 54, 55t
mate drinking, as risk factor for oral cancer, 90
maternal health policy as umbrella for breast and cervical cancer, 219
Mauritius, inverse relationship of consumption and price of smoking in, 183
McGlynn, Katherine A., 147
MD Anderson Cancer Center at the University of Texas, 111
medical records, 250
medications. See drug therapy
men, cancer incidence and mortality of. See gender differences
Merck, 78, 299
methodology, 7b
Metzger, Monika L., 121
Mexico
breast cancer, national health insurance coverage of, 1, 291
cancer services guidelines in, 198
catastrophic health expenditures in, 290
cervical cancer in, 80, 266
childhood cancer in, 1, 125, 204
liver cancer in, 149
Oportunidades program in, 284
percent of total health spending to cancer control in, 15
Seguro Popular (national public insurance program), 1, 125, 204, 266, 283, 284, 287f, 291
smoking in
cigarette taxes in, 10
inverse relationship of consumption and price, 183
knowledge of health information, 184
survival rates due to improved coverage in, 291
universal health care in, 284
m-Health models, 218
Middle East and North Africa. See also specific countries
bladder cancer in, 12
cervical cancer in, 71
colorectal cancer in, 111
HPV vaccination in, 79
types of cancer in, 29
middle-income countries (MICs). See low- and middle-income countries (LMICs)
Million Death Study (India), 39
ministries’ research role, 249–50, 251b
mobile phones, use of, 218
Moldova, pain medications in, 167
Mongolia
HBV vaccination program in, 149
HCV infection in, 151, 155
liver cancer in, 29, 149
opioid accessibility in, 169
morphine, 166, 168, 170, 265f
mortality rates. See cancer death rates
Muñoz, N., 257
Murillo, Raul H., 45
Muslim countries
alcohol consumption levels in, 37
breast cancer screening in, 58
Myanmar, cervical cancer screening in, 74
N
NADF (non-alcoholic fatty liver disease), 147, 154
Namibia, childhood cancer in, 121
National Cancer Institute (U.S.), 215, 255
Surveillance, Epidemiology, and End Results (SEER) Program (U.S.), 251–52
National Comprehensive Cancer Network, 111, 198
National Institute for Health and Care Excellence (UK), 267
National Institute of Alcohol Abuse and Alcoholism (NIAAA), 153–54
national strategies
cancer research, commitments to, 249–62. See also research support
cancer services, universal health coverage of, 4b, 234
collaboration, 256
effectiveness of, 267
intervention packages, 9t
MIC national programs, 234
Native Americans, retinoblastoma among, 137
NCDs. See noncommunicable diseases
neck cancer. See head and neck cancers
needle biopsies, 54, 63
Nepal
B. P. Koirala Memorial Cancer Hospital, 206b
cervical cancer in, 71
HPV vaccination in, 78
opioid accessibility in, 169, 170
pain medications in, 167
Netherlands, smoking restrictions in public places in, 185
Network of National Cancer Institutions of Latin America (RINC) initiative, 245
newborns, HPB vaccination for. See hepatitis B vaccination
New Zealand. See Australia/New Zealand
NGOs. See nongovernmental organizations
NIAAA (National Institute of Alcohol Abuse and Alcoholism), 153–54
Nicaragua, cervical cancer in, 71
Niger
domestic funding in, 282
HPV vaccination in, 78
Nigeria
acute lymphoblastic leukemia (ALL) in, 128
aflatoxins in, 159
breast cancer in, 226
cervical cancer screening in, 75
costs of intervention packages in, 13
non-alcoholic fatty liver disease (NAFD), 147, 154
noncommunicable diseases (NCDs)
allocation of development assistance for, 16
cancer in comparison to other causes of death, 24, 24f
surveillance systems for, 250–51, 252f
tobacco as major contributor to, 187
nongovernmental organizations (NGOs)
cancer prevention activities and funding of, 139, 290
research role of, 250, 256
surgical capacity support from, 234b
Nordhagen, S., 74
Nordic countries. See also specific countries
cervical cancer screening in, 73
liver cancer in, 149, 150
oral cancer in, 88
taxation to finance universal health coverage in, 284
Northern Africa. See Middle East and North Africa
Northern Ireland's greenways urbanization project, effect on chronic diseases, 38
North-South collaborations, 16, 257
Norway
  advertising of cigarettes, ban on, 185
  Ghana-Norway partnership as part of Breast Health Global Initiative, 199
  opioid accessibility in, 170
Nurses' Health Study, 254, 254b
nut chewing, as oral cancer risk, 85, 87, 88–89
nutrition as risk factor for oral cancer, 89
Obermeyer, Z., 74
obesity. See also lifestyle
  relationship to cancer, 37–38
  liver cancer, 147, 154
occult blood test. See colorectal cancer (CRC)
occupational risk factors, 38
Olson, Zachary, 295
Omar, Sherif, 195
opioid accessibility in, 168
opioid medications, 11, 165–69, 167f. See also pain relief
Opioid Price Watch (IAHPC), 167, 170
Opisthorchis viverrini, 36
Oportunidades program (Mexico), 284
oral cancer, 85–99
  alcohol consumption associated with, 37, 89
  chemotherapy, 94, 275
  chronic trauma as risk factor, 90
  cost-effectiveness assessments of interventions, 94–96
  cost-effectiveness of interventions, 94–96, 95f, 268, 274–75t
  defined, 85
  early diagnosis and staging of, 92, 93t
  future research needs, 96
  genetic factors, 89–90
  high-risk screening, 212
  HPV infection and, 87, 88, 90, 218
  incidence and death rates, 6t, 28f, 85–88
    by gender, 86t, 87–88m, 215
    by income group, 87f, 224f
  intervention packages, 9t
  management of, 92
  natural history of, 90
  nutrition as risk factor, 89
  oral potentially malignant disorders (OPMDs), screening for, 91
overview, 85
posttreatment follow-up, 94
prognosis, 94
radiation therapy for, 92–94, 240
research support for, 260
risk factors, 85–90, 218
screening for, 11, 90, 91–92, 218
  health care personnel performing visual screening, 91
  high-risk screening, 212
  self-examination, 91–92
  visual screening, 90–91, 277
surgery, 92–94, 228, 229–30t
  complications of, 94
survival rates, 88
treatment of, 92–94
viruses as risk factor, 90
oral submucous fibrosis (OSMF), 89, 90
Organisation for Economic Co-operation and Development's Global Science Forum, 257
ovarian cancer
deadth rates from, 6t
  high-risk screening, 58, 212
overdiagnosis concerns, 213, 215
oxycodone, 168, 170
P
PAF (population attributable fraction), 26–27
pain relief, 165–73
  availability of broadly defined palliative care services, 167
  barriers in LMICs to, 167–69
  cancer patients' need for, 166
  comprehensive cancer center services, 200
  cost-effectiveness of, 9, 169
  costs of, 14t, 169–70
  Global Opioid Policy Initiative (GOPI), 168, 170–71
  as human right, 165
  International Narcotics Control Board (INCB), 168 in LMICs, 166–67
  opioid medications, availability of, 11, 166–67, 167f
  Opioid Price Watch (IAHPC), 167, 170
  overzealous regulation restricting access to, 168
  patient perspective, 170
Pakistan
  acute lymphoblastic leukemia (ALL) in, 128
  HCV infection in, 151
  incidence of HBV vs. HCV in, 151, 152f
  oral cancer in, 87, 88, 94
Palestinian Authority, breast cancer screening in, 58
Palipudi, Krishna, 175
palliative care. See also pain relief
radiation therapy and, 165, 240, 241
surgery with palliative intent, 230
pancreas cancer, 28f
Pap smears, 69, 73, 74, 216
Papua New Guinea, oral cancer in, 85
Partners in Health, 199
pathology
  comprehensive cancer center services, 199
  research role of, 252
  surgery’s reliance on, 226
telepathology, 218
PBCRs (population-based cancer registries), 25, 39, 251
pediatric cancer. See childhood cancer
Pediatric Oncology in Developing Countries (PODC)
  committee of International Society of Pediatric Oncology (SIOP), 125
Peru
  cervical cancer prevention approaches in, 80
  universal health care in, 284, 287f, 289, 290
Peto, Richard, 179
pharmacotherapy. See chemotherapy
pharmacy services. See also drug therapy
  comprehensive cancer centers, 201
pharynx. See oral cancer
Philip Morris, 189
Philippines
  colorectal cancer incidence rates in, 103
  opioid accessibility in, 170
  smoking in
    implementation of excise tax increases, 184
    implications of tobacco taxation, 10, 188
    inverse relationship of consumption and price, 183
physical inactivity. See lifestyle
"Pink Ribbon Red Ribbon" program, 219
Poland
  opioid accessibility in, 170
  radiation therapy in, 245
  smoking in
    cessation treatments, 186
    implementation of excise tax increases, 184
    inverse relationship of consumption and price, 183
popularity paradox, 215
population attributable fraction (PAF), 26–27
population-based cancer registries (PBCRs), 25, 39, 251
population-based randomized trial, 62
Pramesh, C. S., 223
prevention strategies, 1, 10. See also specific types of cancer
primary health clinic or mobile outreach, 9f
priorities for international support, 16–17
cost reduction for essential intervention packages, 16
research support, 17
technical assistance, 16–17
progressive universalism, 283
prostate cancer
  early detection as factor, 29
  by geographical region, 29
  incidence and death rates, 6t, 27, 28f
    by income group, 32f
  transitions in low- and middle-income countries, 29
  overdiagnosis concerns, 213
  physical inactivity, relationship to, 38
  radiation therapy for, 240
  research support for, 260
  screening for, 10
  lead-time bias and, 212
  prostate-specific antigen (PSA) testing, 10–11
  psychosocial support, 200
public awareness of cancer control interventions, 16, 255
public places, restrictions on smoking in, 185, 188

Q
Qiao, You-Lin, 249, 295
quality-adjusted life years (QALYs), 7b

R
Rabeneck, Linda, 101, 268
Radiation Safety Institute of Canada, 199
radiation therapy (RT), 239–47. See also specific types of cancer
  access to, 243–45, 244m
  as adjuvant treatment, 231, 240
  adoption of expert systems and machine learning methods, 243
  brachytherapy, 241
  comprehensive cancer center services, 199–200, 243
  concurrent chemotherapy and, 240
  constraints on, 265
  cost-effectiveness of, 239
  critical normal structures, limited tolerance of, 240
  delivery methods, 241–43
  equipment specialized for, 239, 265
  externally applied radiation beams, 241
  facilities designed for, 241–42
  infrastructure requirements, 244, 265
  intensity modulated radiation therapy (IMRT), 240
  in multidisciplinary approach to cancer management, 239
  oral cancer, 94
overview, 239–40
palliative treatment and, 165, 240, 241
personnel and radiation therapists, 242, 244
process, 242
radioisotope therapy, 241
safety and quality assurance, 242–43
scaling up, 15, 275
as sole therapy, 240
stereotactic RT, 240
uses of, 240–41
Rajaraman, Preetha, 249
Ramadas, Kunnambath, 85
Ramasundarahettige, Chintanie, 175
raw fish consumption, 157
Reach for Recovery, 58
Rebbeck, Timothy, 249
rectal cancer, 110. See also colorectal cancer
referrals, 214
surgery, 231–32
regional cancer centers, establishment of, 203, 203–4b
registries
childhood cancer incidence rates in, 121, 122f
depth registration systems, linking to cancer registration systems, 253
global initiative for cancer registry through IARC, 40, 40m
importance of, 266
population-based cancer registries (PBCRs), 25, 39, 251
types of data in, 250–52
reproductive health policy as umbrella for breast and cervical cancer, 159
Republic of Korea. See Korea, Republic of research support, 17, 249–62
“best buys,” 259–60
biobanking, 252–53
budget allocation recommended for, 249
Call to Action for Research on Health (2008 Bamako Forum), 249, 250b
cancer registries, data in, 250–52
case-control studies, 253
cervical cancer as integrated research exemplar, 257–59
cohort studies, 254, 254–55b
collaboration, 256
education to include, 256
epidemiologic studies, 253–57, 260
health care professionals’ role in, 250
health communications, 255
health surveillance and cancer surveillance, 250–51
hospitals’ role in, 250
implementation science, 255–56, 256b
as “best buy” for cancer research, 259
industry collaboration, 257
international collaboration, 257
laboratories and anatomic pathology, 252
linking death registration systems to cancer registration systems, 253
local level collaboration, 256
ministries’ role in, 249–50
national level collaboration, 256
overview, 249
priorities in cancer research, 250–57
research training, 256–57
stakeholders’ knowledge needs and, 249–50, 251b
transport of specimens among countries, 253, 256
resource limitations
availability across countries, 264–67
comprehensive cancer centers, 202–5
need for guidelines to address, 48–49
surgery, 226–27, 227b
retinoblastoma, 137–38
Rodriguez-Galindo, Carlos, 121
Romania, opioid accessibility in, 169, 170
Russia
alcohol consumption levels in, 37
breast cancer detection in, 52
colon cancer incidence and mortality in, 266
HCV treatment in, 156
health insurance coverage in, 266
liver cancer, cost of treatment in, 159
liver fluke infection in, 154
oral cancer in, 88
smoking in, 180
knowledge of health information, 184
price elasticity, 181
Rwanda
cervical screening and treatment services in, 228
HPV vaccination program in, 78
opioid accessibility in, 169
Rwandan Women’s Interassociation Study and Assessment, 73
S
St. Jude Children’s Research Hospital (Memphis, Tennessee), 130, 136, 204, 205b
Sankaranarayanan, Rengaswamy, 1, 85, 114, 217, 258, 268
Sauvaget, C., 114, 217
Sayginsoy, O., 187
scaling up
cancer screening projects, 214
chemotherapy, 16, 275
childhood cancer, 277
hepatitis B vaccination, 15
HPV vaccination, 15
surgical systems, 234–35
Schistosoma haematobium, 36
schistosomiasis, 12
screening. See cancer screening; specific types of cancer
secondhand smoke, 175
SEER (Surveillance, Epidemiology, and End Results)
Program, 102
Seguro Popular (Mexico), 1, 125, 204, 266, 283, 284, 287, 291
self-examination
breast self-examination, 52, 216
oral cancer screening, 91–92
Sharma, Monisha, 295
Shi, Ju-Fang, 295
Shulman, L., 214
Sierra Leone, HPV vaccination in, 78
simeprevir, 155–56, 159
Singapore
colorectal cancer in, 108, 111
head and neck cancers, imaging techniques for, 198
health insurance coverage in, 289
liver fluke infection in, 154
oral cancer in, 88
Single Convention on Narcotic Drugs of 1961, 168
SIOP (International Society of Pediatric Oncology), 125
skilled medical personnel, 266
skin cancer, 38, 240, 260
Slovak Republic, oral cancer in, 87, 88
smoking. See tobacco use
smuggling and black market sales of cigarettes, 186–87
sociocultural beliefs. See cultural practices
Soerjomataram, Isabelle, 23
sofosbuvir, 155–56, 159
South Africa
breast cancer and access to treatment in, 225
cervical cancer prevention approaches in, 80, 217
national health insurance package in, 15
smoking in
cigarette taxes, 10, 184
inverse relationship of consumption and price, 183, 183f
reporting on death certificates, 185
smuggling and black market sales of cigarettes, 187
South Asia
catastrophic health expenditures in, 282
colorectal cancer in, 38, 102
HBV infection in, 151
HCV infection in, 155
head and neck cancers in, 198
high-risk screening for oral cancer in, 212
imaging techniques guidelines for head and neck cancers, 198
oral cancer in, 85, 87, 89, 212, 218
tobacco use in, 175
Southeast Asia
aflatoxins in, 153
alcohol consumption in, 157
breast cancer in, 60
colorectal cancer in, 38, 114
oral cancer screening in, 87, 218
high-risk screening, 212
South-South collaborations, 16, 257
Spain
liver cancer in, 149
opioid accessibility in, 170
smuggling and black market sales of cigarettes in, 187
specialized cancer centers/units. See also comprehensive cancer centers
childhood cancer dedicated centers, 123–24, 124f, 128
intervention packages, 9t
scaling up, 16
Standards of Oncology Pharmacy Practice, 201
Stevens, Lisa, 249
stomach cancer
diet and consumption associated with, 37
incidence and death rates, 6t, 8f, 27, 28f, 215, 218
decline in, 29
by income group, 35f
research support for, 260
schistosomiasis and, 12
screening for, 218
stroke, smoking’s relationship to, 178, 184
Subramanian, Sujha, 85
Sub-Saharan Africa
alcohol consumption in, 157
antiretroviral therapy in, 73
Burkitt lymphoma in, 123, 134
cancer incidence and death rates in, 166
cancer trends in, 29
cervical cancer in, 23, 71, 71m
childhood cancer in, 121
costs of intervention packages in, 13–14
HBV infection in, 151
HCV infection in, 155
HPV vaccination in, 10, 79
liver cancer in, 147, 149, 151
national health insurance coverage in, 290
radiation therapy in, 244, 265, 266
resource constraints in, 264
retinoblastoma in, 137
surgical infrastructure needed in, 223
Substance Abuse and Mental Health Services Administration, 255–56
Sudan
  cervical cancer in, 71
  opioid accessibility in, 170
  oral cancer, smokeless tobacco products as factor in, 89
  pain medications in, 167
Sullivan, Richard, 211, 223
Sullivan, Terrence, 211
surgery, 223–38
  access to, 225, 225r
  adjuvant treatment considerations, 230–31, 240
  anesthesia, safe provision of, 226
  biopsy procedures, 227–28
  breast cancer, 12h, 54, 55–56t, 223
  burden of surgically treatable cancers in LMICs, 224, 224f, 236
  capacity building, 232–35
  centralized vs. decentralized delivery models, 231, 231r
  cervical cancer, 78
  colon cancer, 110, 223
  comprehensive cancer center services, 199
  costs and cost-effectiveness of, 235–36, 267
  diagnostic role of, 227
  distribution of services, 225
  guidelines for surgical platforms, 227–31
  imaging in conjunction with, 226
  infrastructure and training, 225–26, 232–33, 264–65
  need for further study to assess effectiveness of, 235, 236, 267
  nonphysician providers, task shifting to, 232
  oral cancer, 92–94
    complications of, 94
  overview, 223
  pain relief and, 165
  pathology in conjunction with, 226
  platforms for delivery, 227–31, 228–30r
  private vs. public sector provision of services, 234
  procurement processes, 233
  quality and safety, 225–26, 233, 233–34b
  rectal cancer, 110
  referral networks, service coordination, and partnerships, 231–32
  resources
    availability across countries, 264–65, 265r
    stratified approaches by level of care, 226–27, 227b
  scaling up, 15, 16, 234–35
  shortage of surgeons in LMICs, 232–33
  standardization of guidelines, 225
  status in LMICs, 224–25
  surgical missions, 232
  treatment with curative intent, 228–30
treatment with palliative intent, 230
  utilization of services, 225
  workforce development for, 232–33
Surveillance, Epidemiology, and End Results (SEER) Program, 102
surveillance systems, 250–51, 252r
  as “best buy” for cancer research, 259
  need for, 24, 26, 39–40
survivorship programs, 200
Sweden
  alcohol consumption levels in, 37
  cervical cancer treatment in, 16
Switzerland, smoking in
  knowledge of health risks associated with, 185
  possible tax increase on cigarettes, 184
  treaty with Uruguay as basis for lawsuit, 189
TTaiwan
  colorectal cancer in, 108, 111
  HCV infection in, 151
  hepatitis B vaccination in, 36
  incidence of HBV vs. HCV in, 151, 152f
  liver cancer in, 149, 159
  oral cancer in, 85, 87, 92
  tamoxifen, 12h, 54, 60, 231, 265r
Tanzania
  cervical cancer screening in, 75
  HPV vaccination in, 78
  technical assistance, need to prioritize, 16–17
  teledicine, 218
telepathology, 218
Thailand
  care availability, outcomes of increasing, 291
  cervical cancer prevention approaches in, 80–81, 292
  colorectal cancer in, 103, 108, 217
  financing of cancer interventions from taxes in, 290
  liver cancer in, 149
  liver fluke infection in, 149, 154, 158
  oral cancer in, 88, 94
  smoking in
    implications of tobacco taxation, 188
    inverse relationship of consumption and price, 183
    knowledge of health information, 185
  universal health care in, 284, 288r, 289, 290
  co-payments, 291
Thomas, David B., 45
Three-Step Analgesic Ladder (WHO), 166
Thun, M. J., 254
thyroid cancer
  by geographical region, 29
  incidence and death rates, 28f
tissue sampling, 54, 63, 227–28

tobacco taxes, 180–84
  ad valorem taxes, 182
  affordability and, 182
  cost-effectiveness of, 13, 13f, 187
  discouraging youth smoking, 10, 182
  financing of cancer interventions from, 15, 290
  implementation of large tax increases, 183–84, 183f
  poverty considerations, 188
  price elasticity of demand for tobacco, 181–82
  signaling effects of price increases, 184
  smart excise tax structure, 182–83, 184f

tobacco use, 175–93. See also oral cancer; tobacco taxes
  advertising of cigarettes, 185, 189
  cancer and other diseases resulting from, 176–78
  chronic lung disease and, 178
  colorectal cancer and, 32
  cost-effectiveness of tobacco control, 187–88, 187–88f
  current global volume of, 180
e-cigarettes, 186
  epidemiology of smoking-attributable diseases, 175–79
  Framework Convention on Tobacco Control (FCTC), 10, 89, 188, 189
  future burden of cancer and, 32, 34–36, 179
  gender differences in, 29–30, 176, 177f, 180
  Global Adult Tobacco Survey, 182, 184
  globalization and, 189
  Global Youth Tobacco Survey, 182
  individuals who start smoking in adolescence or early adult life, 176, 176f, 177f, 181f
  international initiatives, 189
  intervention packages, 9f
  cost-effectiveness of, 8
  costs of, 14f
  effectiveness of, 10, 182f
  mortality rates, 35, 175, 179
  avoidable deaths before 2050, 189
  cessation of use, effect on, 178
  in LMICs, 178–79
  smoking’s delayed effect on, 175–76
  plain packaging mandate, 185, 189
  population attributable fraction (PAF) and, 26
  poverty considerations for, 188
  public places, restrictions on smoking in, 185, 188
  as risk factor, 23, 85, 87, 88–89
  smokeless tobacco use, 88–89
  smoking cessation
    counseling and cessation support programs, 186
    health information and counter-advertising, 184–85
  interventions to increase, 180–87. See also tobacco taxes
    patterns, 180
    smuggling and black market sales of cigarettes, 186–87
    supply-side interventions, 186–87
    tuberculosis and, 178
    Uruguay case study of tobacco control, 188–89
    U.S. ban of clove-flavored cigarettes, WTO suit over, 189
    WTO suits involving cigarettes, 189
    traditional medicine, 155
    training of health care professionals, 203–4
      in radiation therapy, 244
      surgeons and surgical staff, 225–26, 232–33
      transport of specimens among countries, 253, 256
    trastuzumab, 12
    Trimble, Edward L., 249
    Trypuc, Joann, 195
    tuberculosis, 176, 178
    Tufts Medical Center Cost-Effectiveness Analysis Registry of cancer-related studies, 235
    tumor lysis syndrome (TLS), 135
    Tunisia, cervical cancer in, 71

Turkey
  financing approach in, 283
  radiation therapy in, 245
  smoking, inverse relationship of consumption and price in, 183

  twinning programs
    childhood cancer treatment, 124–25, 130, 140
    development of cancer centers and, 205
    examples of, 205–6b, 267
    innovative approaches and, 218
    pathology and laboratory medicine, 199
    survival rates improved by, 205

  U
  Uganda
    alcohol consumption levels in, 37
    cancer trends in, 29
    cervical cancer in, 23, 75
    opioid accessibility in, 169
  Uganda Cancer Institute, 205b
  ultrasound in breast cancer diagnosis, 54, 216
  Unidad Nacional de Oncología Pediátrica (UNOP, Guatemala), 140
  Union for International Cancer Control (UICC), 197b
    Global Task Force on Radiotherapy for Cancer Control, 245
  Tumor, Nodes, Metastasis (TNM) staging system, 92

United Kingdom
  asbestos exposure and lung cancer in, 38
breast cancer, new drug treatments for, 13
British doctors, cohort study of, 254
British Royal College of Physicians, 185
HCV treatment in, 156
National Institute for Health and Care Excellence, 267
opioid accessibility in, 170
oral cancer in, 88
quitting smoking’s effect on mortality in, 178
salt intake, related to cancer rate in, 37
smoking in
   effect on mortality in, 175–76, 177f
   inverse relationship of consumption and price, 183, 183f
quitting, effect on cancer, 178, 180
taxation to finance universal health coverage in, 284
United Kingdom Million Women Study, 254
United Nations (UN)
   demographic estimates of cancer mortality, 7b
   Sustainable Development Goals for 2030, 1
United Nations Population Fund, 219
United Nations World Population Prospects, 26
United States
   acute lymphoblastic leukemia (ALL) in, 128
   alcohol consumption in, 157
   cancer registries in, 266
   colorectal cancer incidence rates in, 102
   cost-effectiveness in, 267
   incidence of HBV vs. HCV in, 151, 152f
   liver cancer in, 149, 150
   liver cirrhosis in, 154
   lung cancer in, 177
   asbestos exposure and, 38
   opioids for pain relief in, 169
   oral cancer, smokeless tobacco products as factor for, 89
   smoking in, 180
   advertising of cigarettes, 185
   ban of clove-flavored cigarettes, WTO suit over, 181–82
   e-cigarettes, 186
   effect on mortality in, 176, 177f
   implementation of excise tax increases, 184, 187
   inverse relationship of consumption and price, 183, 183f
   price elasticity, 181–82
   quitting, effect on mortality, 178, 179f
   U.S. Surgeon General’s Report, 185
   youth quitting, 184
   surgery in, 236
universal health coverage. See health insurance
urbanization, 263, 277
Uruguay
colorectal cancer in, 11
oral cancer in, 85
tobacco control in, 188–89
U.S. Community Preventive Services Task Force, 157
U.S. Multi-Society Task Force on CRC/American Cancer Society (USMSTF), 107, 108
U.S. Preventive Services Task Force (USPSTF), 10–11
on breast self-examination, 52
on clinical breast examination, 51
on colorectal screenings, 107–8
on mammogram screenings, 50, 51f
on oral cancer, 91, 218
on screening guidelines, 198
U.S. Surgeon General’s Report, 185

V
vaccines. See hepatitis B (HBV) vaccination; HPV (human papillomavirus) vaccination
Verguet, Stéphane, 295
Victoria Hospice (Victoria, British Columbia), 206b
Vietnam
   breast cancer in
      clinical breast examinations, 60
      surgical treatment costs, 235
   liver cancer in, 149
   liver fluke infection in, 154
   opioid accessibility in, 168–69
   smoking in
      affordability, 182
      implications of tobacco taxation, 188
      knowledge of health information, 184
Vos, T., 267

W
Wagner, Judith, 165
Wang, Shao-Ming, 295
Wee, J. T., 198
Welch, Gilbert, 215
West Africa, aflatoxins in, 157
WHO. See World Health Organization
Wild, Christopher P., 147
Wilms tumor, 11, 126, 133–34, 133f, 135f
Wilson-Junger screening criteria, 213, 213b
women. See also gender differences
breast cancer. See breast cancer
cervical cancer. See cervical cancer
ovarian cancer. See ovarian cancer
World Development Report (1993), 5b
World Economic Forum/Harvard School of Public Health, 218
World Endoscopy Organization, 109
World Endoscopy Society, 267
World Health Assembly
premature death, goal to reduce, 1
smoking, goal to reduce, 189
World Health Organization (WHO). See also
  International Agency for Research on Cancer
  (IARC)
on breast cancer guidelines, 48
cervical cancer screening, VIA demonstration
  project, 75
Choosing Interventions That Are Cost-Effective
  (WHO-CHOICE) framework, 59, 60, 277
on cigarette excise taxes, 183–84
collection of cancer incidence, 39
on cost-effective intervention strategies for NCDs in
  LMICs, 218
cost effectiveness recommendations, 60, 138, 235
on effectiveness of tobacco control, HPV and HBV
  vaccination, and opportunistic cervical cancer
  screening, 17
EPIC model to simulate the macroeconomic effects
  of noncommunicable diseases, 187, 187t
Essential Medicines List, 156, 166, 170
Framework Convention on Tobacco Control
  (FCTC), 10, 89, 188, 189
Global Health Estimates, 7b
Global Health Observatory, 250
Global Monitoring Framework for
  Noncommunicable Diseases, 166
on HBV vaccine, 155
on HCV infection, 151
on health expenditures covered by external sources,
  282, 283
on imaging guidelines, 199
on life table estimates for China, 297
mortality databank, 26
MPOWER report on global tobacco epidemic, 36
on national cancer control planning, 195, 243, 267
on noncommunicable disease best buys for LMICs, 8
on palliative care, 165, 168
Study of Global AGEing and Adult Health, 298
Surgical Safety Checklist, 199
Three-Step Analgesic Ladder, 166
WHO Action Plan for the Global Strategy for the
  Prevention and Control of Noncommunicable
  Diseases, 39
World Trade Organization (WTO), 189
Y
Yerramilli, Pooja, 281
Yip, Cheng-Har, 223
youth smoking, 10, 182, 184, 186
Yurekli, Ayda, 175, 187
Z
Zambia, cervical cancer in, 71, 75
Zatorfiksi, Witold, 175
Zauber, Ann G., 101
Zelle, S. G., 59, 60, 216
Zhao, Fang-hui, 249
Zimbabwe
  cancer trends in, 29
  cervical cancer, increases in, 23
zur Hausen, H., 257
ECO-AUDIT

Environmental Benefits Statement

The World Bank Group is committed to reducing its environmental footprint. In support of this commitment, the Publishing and Knowledge Division leverages electronic publishing options and print-on-demand technology, which is located in regional hubs worldwide. Together, these initiatives enable print runs to be lowered and shipping distances decreased, resulting in reduced paper consumption, chemical use, greenhouse gas emissions, and waste.

The Publishing and Knowledge Division follows the recommended standards for paper use set by the Green Press Initiative. The majority of our books are printed on Forest Stewardship Council (FSC)—certified paper, with nearly all containing 50–100 percent recycled content. The recycled fiber in our book paper is either unbleached or bleached using totally chlorine free (TCF), processed chlorine free (PCF), or enhanced elemental chlorine free (EECF) processes.

More information about the Bank’s environmental philosophy can be found at http://crinfo.worldbank.org/wbcrinfo/node/4.